These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

536 related articles for article (PubMed ID: 37833948)

  • 1. Anti-Amyloid Therapies for Alzheimer's Disease and the Amyloid Cascade Hypothesis.
    Fedele E
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clarity on the blazing trail: clearing the way for amyloid-removing therapies for Alzheimer's disease.
    Lian Y; Jia YJ; Wong J; Zhou XF; Song W; Guo J; Masters CL; Wang YJ
    Mol Psychiatry; 2024 Feb; 29(2):297-305. PubMed ID: 38001337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of monomeric amyloid-β in cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies.
    Imbimbo BP; Ippati S; Watling M; Imbimbo C
    Pharmacol Res; 2023 Jan; 187():106631. PubMed ID: 36586644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of amyloid beta-directed antibodies against Alzheimer's disease: Twists and turns.
    Lu D; Dou F; Gao J
    Drug Discov Ther; 2023; 17(6):440-444. PubMed ID: 38220210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lessons learned from the failure of solanezumab as a prospective treatment strategy for Alzheimer's disease.
    Lozupone M; Dibello V; Sardone R; Castellana F; Zupo R; Lampignano L; Bortone I; Stallone R; Altamura M; Bellomo A; Daniele A; Solfrizzi V; Panza F
    Expert Opin Drug Discov; 2024 Jun; 19(6):639-647. PubMed ID: 38685682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Passive Immunotherapies Targeting Amyloid-
    Marković M; Milošević J; Wang W; Cao Y
    Mol Pharmacol; 2023 Dec; 105(1):1-13. PubMed ID: 37907353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.
    Sevigny J; Chiao P; Bussière T; Weinreb PH; Williams L; Maier M; Dunstan R; Salloway S; Chen T; Ling Y; O'Gorman J; Qian F; Arastu M; Li M; Chollate S; Brennan MS; Quintero-Monzon O; Scannevin RH; Arnold HM; Engber T; Rhodes K; Ferrero J; Hang Y; Mikulskis A; Grimm J; Hock C; Nitsch RM; Sandrock A
    Nature; 2016 Sep; 537(7618):50-6. PubMed ID: 27582220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What's in It for Me? Contextualizing the Potential Clinical Impacts of Lecanemab, Donanemab, and Other Anti-β-amyloid Monoclonal Antibodies in Early Alzheimer's Disease.
    Jin M; Noble JM
    eNeuro; 2024 Sep; 11(9):. PubMed ID: 39332901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the Potential of Therapeutic Agents Targeted towards Mitigating the Events Associated with Amyloid-β Cascade in Alzheimer's Disease.
    Behl T; Kaur I; Fratila O; Brata R; Bungau S
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33050199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer's Disease.
    Mukhopadhyay S; Banerjee D
    J Alzheimers Dis; 2021; 83(4):1537-1552. PubMed ID: 34366359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Critical Appraisal of Amyloid Lowering Agents in AD.
    Decourt B; Boumelhem F; Pope ED; Shi J; Mari Z; Sabbagh MN
    Curr Neurol Neurosci Rep; 2021 Jun; 21(8):39. PubMed ID: 34110536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.
    Tolar M; Abushakra S; Hey JA; Porsteinsson A; Sabbagh M
    Alzheimers Res Ther; 2020 Aug; 12(1):95. PubMed ID: 32787971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Amyloid Immunotherapies for Alzheimer's Disease: A 2023 Clinical Update.
    Yadollahikhales G; Rojas JC
    Neurotherapeutics; 2023 Jul; 20(4):914-931. PubMed ID: 37490245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updates on pharmacological treatment for Alzheimer's disease.
    Tipton PW
    Neurol Neurochir Pol; 2024; 58(2):150-160. PubMed ID: 37606550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
    Silvestro S; Valeri A; Mazzon E
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid Beta Hypothesis in Alzheimer's Disease: Major Culprits and Recent Therapeutic Strategies.
    Vijayan D; Chandra R
    Curr Drug Targets; 2020; 21(2):148-166. PubMed ID: 31385768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anti-Amyloid Antibody Therapy for Alzheimer's Disease].
    Shinohara M; Ono K
    Brain Nerve; 2024 Oct; 76(10):1119-1125. PubMed ID: 39370836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid-Directed Antibodies: Past, Present, and Future.
    Noorda K; Noorda K; Sabbagh MN; Bertelson J; Singer J; Decourt B
    J Alzheimers Dis; 2024; 101(s1):S3-S22. PubMed ID: 39422953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Single Toxin Origin of Alzheimer's Disease and Other Neurodegenerative Disorders Enables Targeted Approach to Treatment and Prevention.
    Tolar M; Hey JA; Power A; Abushakra S
    Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.